NEW ORLEANS -- Elite college and professional athletes diagnosed with genetic heart disease can still suit up, provided a comprehensive return-to-play protocol is implemented, a retrospective study ...
MALVERN, Pa., March 12, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or ...
“In our study, Black patients with TED presented with fewer clinical exam features based on current classification guidelines, but had longer follow-up and underwent similar treatments as White ...
CAMBRIDGE, Mass., June 5, 2025 /PRNewswire/ -- Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drug candidates that address the root causes of ...
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data presentations in support of its preclinical drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results